1，6-二磷酸果糖联合西药改善慢性心力衰竭患者心功能的meta分析和GRADE质量评价

doi:10.20047/j.issn1673-7210.2023.20.17

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1564 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the effect and evidence level of 1, 6-diphosphate fructose combined with western medicine on improving cardiac function in patients with chronic heart failure (CHF). Methods Randomized controlled trials on the use of 1, 6-diphosphate fructose in treating patients with CHF were searched through CNKI, Wanfang Data, VIP, China Biomedical Literature Service System, PubMed, and Web of Science from inception to November 2022. Literatures management, meta analysis, and outcome indicators were evaluated by Endnote 20.0, Review Manager 5.4.1, and GRADE profiler. Results A total of nine literatures were included, involving 771 subjects, including 388 in the experimental group and 383 in the control group. The results of meta analysis showed that left ventricular ejection fraction [MD=5.00, 95%CI: 4.91-5.09, P=0.000 01], E/A[MD=0.10, 95%CI: 0.04-0.16, P=0.000 08], cardiac output index [MD=0.61, 95%CI: 0.38-0.83), P=0.000 01], cardiac output [MD=0.73, 95%CI: 0.36-1.10, P=0.000 1] of experimental group were higher than those of control group. GRADE quality evaluation suggested that the evidence levels of the included literatures were low. Conclusion 1, 6-diphosphate fructose combined with western drugs can improve cardiac function in patients with CHF, but high-level evidence is still needed.

Key words： 1, 6-diphosphate fructose Chronic heart failure Cardiac function Meta analysis GRADE quality evaluation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHA Yuling1　LI Jun2

Cite this article:

ZHA Yuling1　LI Jun2. Meta analysis and GRADE quality evaluation of 1, 6-diphosphate fructose combined with western medicine in improving cardiac function of patients with chronic heart failure[J]. 中国医药导报, 2023, 20(20): 81-85.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.20.17 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I20/81

[1] Lopaschuk GD. Metabolic Modulators in Heart Disease：Past，Present，and Future [J]. Can J Cardiol，2017，33（7）：838-849.
[2] 陈楠楠，薛一涛.中药干预慢性心力衰竭线粒体能量代谢的研究进展[J].世界中医药，2022，17（3）：437-440.
[3] Fukushima A，Milner K，Gupta A，et al. Myocardial Energy Substrate Metabolism in Heart Failure：from Pathways to Therapeutic Targets [J]. Curr Pharm Des，2015，21（25）：3654- 3664.
[4] 雷印胜，范全心，郭兰敏，等.1，6-二磷酸果糖对促炎性细胞因子释放的影响[J].中国体外循环杂志，2003，1（2）：69-71.
[5] 赵小朋，柳国胜.1，6-二磷酸果糖对缺氧缺血性心、脑损害的保护作用（综述）[J].暨南大学学报（自然科学与医学版），2003，24（4）：91-95.
[6] 李少辉，周如君.1，6二磷酸果糖对心脏瓣膜置换术患者心肌的保护作用[J].中国老年学杂志，2015，35（4）：992- 994.
[7] 王青伟，李悦，刘强，等.1，6-二磷酸果糖口服液对急性心肌梗死大鼠心肌细胞凋亡、氧化应激和能量代谢的影响及可能机制研究[J].实用心脑肺血管病杂志，2022，30（5）：40-44.
[8] 王华，梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[9] Bozkurt B，Coats AJS，TsutsuiH，et al. Universal definition and classification of heart failure：a report of the Heart Failure [J]. Eur J Heart Fail，2021，23（3）：352-380.
[10] Balshem H，Helfand M，Schünemann HJ，et al. GRADE guidelines：3. Rating the quality of evidence [J]. J Clin Epidemiol，2011，64（4）：401-406.
[11] 朱云.1，6-二磷酸果糖对老年慢性心衰患者血浆TNF、ET、RAS的影响[J].中国实用医药，2007，2（16）：30-31.
[12] 王志男.1，6-二磷酸果糖与小剂量美托洛尔联合治疗难治性心力衰竭疗效观察[J].心血管康复医学杂志，2001,10（4）：331-333.
[13] 刘奇良，张大维.1，6-二磷酸果糖治疗充血性心力衰竭临床及血流动力学观察[J].上海医药，2000（7）：23-24.
[14] 史文莉.1，6-二磷酸果糖治疗冠心病心力衰竭124例疗效观察[J].陕西医学杂志，2005，34（7）：870-871.
[15] 蒋佳瑶，刘丽.1，6-二磷酸果糖治疗心力衰竭临床疗效观察[J].临床医药实践，2006，15（5）：368.
[16] 杨维明.1.6-二磷酸果糖佐治冠心病心绞痛伴心力衰竭的疗效[J].心脑血管病防治，2009，9（3）：234-235.
[17] 贾鸣，潘琪宏，王迎.二磷酸果糖治疗重症充血性心力衰竭的临床疗效[J].中国临床药学杂志，2004，13（3）：136-138.
[18] 曲娜，张斌，陆卫东，等.FDP对冠心病合并心力衰竭老年患者的疗效[J].同济大学学报，2008，29（5）：129-131.
[19] 马丽娟，齐晓云.1，6-二磷酸果糖治疗慢性心力衰竭[J].中国水电医学，2006（2）：74-75
[20] Zhu X，Li H，Zhang C. Clinical effects of Ganglioside and fructose-1，6-diphosphate on neonatal heart and brain injuries after Asphyxia [J]. Pak J Med Sci，2017 ，33（5）：1199-1204.
[21] Wilches-Buitrago L，Viacava PR，Cunha FQ，et al. Fructose 1，6-bisphosphate inhibits osteoclastogenesis by attenuating RANKL-induced NF-κB/NFATc-1 [J]. Inflamm Res，2019，68（5）：415-421.
[22] Dias HB，de Oliveira JR，Donadio MVF，et al. Fructose-1，6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts [J]. PLoS One，2019，14（9）：e0222202.
[23] Li CH，Chan MH，Chang YC. The role of fructose 1，6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis [J]. Aging（Albany NY），2022，14（7）：3233- 3258.
[24] 李卓，陈燕娟，刘士华.1，6-二磷酸果糖三钠盐复方制剂的毒理学研究[J].中国老年保健医学，2020，18（1）：10-12.
[25] Guyatt GH，Oxman AD，Vist GE，et al. GRADE：an emerging consensus on rating quality of evidence and strength of recommendations [J]. BMJ，2008，336（7650）：924-926.
[26] 杨强，丁君灿，罗紫月，等.钠-葡萄糖协同转运蛋白2抑制剂通过改善心肌能量代谢治疗慢性心力衰竭的研究进展[J].江苏医药，2023，49（3）：311-315.